Conti P, Bartle L, Barbacane R C, Reale M, Placido F C, Sipe J
Immunology Division, University of Chieti Medical School, Italy.
Immunol Invest. 1995 Mar;24(3):523-35. doi: 10.3109/08820139509066848.
Serum amyloid A (SAA) protein is a major acute phase reactant in human and many other species. Infections and traumatic inflammation are characterized by a rapid increase of SAA; its concentration in the plasma may augment many-fold. Cytokines such as IL-1 and IL-6 are considered mediators of acute phase protein synthesis. The most accredited mechanism of action of IL-1 in inflammatory diseases is the stimulation of PGE2 release, which is highly dependent on the concentration of IL-1. In this study we found that human Hep 3B hepatoma cells treated with the combination of hrIL-6 (10ng/ml) plus hrIL-1 (1ng/ml) produced an augmentation in steady-state levels of SAA mRNA (87%) compared to hrIL-6 (10ng/ml) plus PGE2 (5 microM), which induced an increase of only 33%, compared to IL-6 alone, while cells treated with hrIL-6 plus PGE2 (0.5 microM) had a similar effect as hrIL-6 did alone. Moreover, the addition of exogenous PGE2 (5 microM) to the cell cultures produced no significant increase in concentration of SAA mRNA compared to the control. In addition, according to the data obtained by the blot analysis we also found, by ELISA method, that hrIL-6 acts in synergism with hrIL-1 on SAA protein secretion in human Hep 3B hepatoma cell cultures after 48 h incubation. In fact, the cell cultures treated with hrIL-6 plus hrIL-1 caused a higher release approximately 1.5-4-fold of SAA protein than the cells treated with IL-6 plus PGE2 5 microM or IL-1 + PGE2 5 microM, respectively. The synergistic effect of hrIL-6 plus hrIL-1 beta was inhibited by hrIL-1 receptor antagonist (hrIL-1ra) 50 micrograms/ml, a protein which specifically binds to the IL-1 receptor and is structurally similar to IL-1 beta but with no IL-1-like activity; while indomethacin (5 microM) was ineffective. These results strongly suggest that the synergism between hrIL-6 plus hrIL-1 on the transcription and the protein release of SAA release is not due to a PGE2-dependent process in human Hep 3B hepatoma cells. This finding highlights a specific biological effect of IL-1 not in relation to PGE2, suggesting a specific mechanism of action for IL-1 in regulating acute phase protein synthesis.
血清淀粉样蛋白A(SAA)是人类和许多其他物种中的一种主要急性期反应物。感染和创伤性炎症的特征是SAA迅速增加;其在血浆中的浓度可能会增加许多倍。诸如白细胞介素-1(IL-1)和白细胞介素-6(IL-6)等细胞因子被认为是急性期蛋白合成的介质。IL-1在炎症性疾病中最被认可的作用机制是刺激前列腺素E2(PGE2)的释放,这高度依赖于IL-1的浓度。在本研究中,我们发现,与IL-6(10ng/ml)加PGE2(5 microM)相比,用人重组白细胞介素-6(hrIL-6,10ng/ml)加人重组白细胞介素-1(hrIL-1,1ng/ml)处理的人Hep 3B肝癌细胞产生的SAA mRNA稳态水平增加了87%,而IL-6(10ng/ml)加PGE2(5 microM)仅诱导增加33%,与单独使用IL-6相比,而用hrIL-6加PGE2(0.5 microM)处理的细胞具有与单独使用hrIL-6相似的效果。此外,与对照相比,向细胞培养物中添加外源性PGE2(5 microM)并未使SAA mRNA浓度显著增加。此外,根据印迹分析获得的数据,我们还通过酶联免疫吸附测定(ELISA)方法发现,在孵育48小时后,hrIL-6与人重组白细胞介素-1β(hrIL-1β)在人Hep 3B肝癌细胞培养物中对SAA蛋白分泌具有协同作用。事实上,与分别用IL-6加5 microM PGE2或IL-1加5 microM PGE2处理的细胞相比,用hrIL-6加hrIL-1处理的细胞培养物导致SAA蛋白释放量高出约1.5至4倍。hrIL-6加hrIL-1β的协同作用被50微克/毫升的人重组白细胞介素-1受体拮抗剂(hrIL-1ra)抑制,hrIL-1ra是一种与IL-1受体特异性结合且结构与IL-1β相似但无IL-1样活性的蛋白质;而吲哚美辛(5 microM)无效。这些结果强烈表明,hrIL-6加hrIL-1对SAA释放的转录和蛋白质释放的协同作用不是由于人Hep 3B肝癌细胞中依赖PGE2的过程。这一发现突出了IL-1与PGE2无关的一种特定生物学效应,表明IL-1在调节急性期蛋白合成中具有特定的作用机制。